Adoption of Clinical Technology
NEW YORK, NY and DUBLIN, IRELAND –March 6, 2007 – Medidata Solutions, a global provider of electronic clinical data capture (EDC), management and reporting solutions, and ICON, a global provider of outsourced development services, today reached a two-year milestone in their partnership.
Since February 2005, the companies have worked together to deliver Medidata’s Rave EDC platform to biopharmaceutical companies around the globe and to date, ICON and Medidata have been awarded contracts from 19 companies for 37 clinical trials across Phases I-IV, in a range of therapeutic areas.
ICON, an early adopter of EDC technology, was Medidata’s first ASPire to Win™ partner. This program, which is based on a non-exclusive application service provider (ASP) partnership and business model, has enabled ICON to meet sponsor demand for Medidata Rave®. ICON has been able to offer the platform in-house by building and deploying studies with Rave certified resources, while the program has also allowed Medidata to implement Rave with a range of sponsors looking to streamline global clinical trials.
“ICON’s proven ability to provide clinical research process and data management expertise complements Medidata’s industry-leading technology and hosting services, offering sponsors a robust and flexible Rave implementation model,” said Tarek Sherif, CEO of Medidata Solutions. “We value our partnership with ICON and anticipate further success in 2007.”
Tom O’Leary, Global Head of Data Management at ICON, added, “Our partnership with Medidata has proven extremely beneficial in enabling us to offer our growing customer base with a user-friendly, flexible solution to help drive further adoption of EDC for clinical trials worldwide. We look forward to building on the success of the past two years as we continue to provide innovative solutions to clients throughout 2007 and beyond.”
Through this partnership, ICON and Medidata will continue to work together on marketing initiatives that demonstrate how EDC technology adoption can significantly enhance the clinical trials process.
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data – the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing life-enhancing treatments to market – on six continents and in more than 80 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com.
About ICON
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has over 4800 employees, operating from 50 locations in 30 countries. Further information is available at www.iconclinical.com